Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Cancers
|
April 12, 2022
Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma
Marc Hilmi, Cindy Neuzillet, Jérémie H Lefèvre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
Alice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Experimental Hematology & Oncology
|
July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Stefano Kim, Véronique Vendrely, Angélique Saint, et al.
Cancer Treatment Reviews
|
July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective
Judith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
Lancet (London, England)
|
June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial
Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
The Lancet. Oncology
|
April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study
Mélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Clinical Colorectal Cancer
|
August 2, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
Emmanuelle Samalin, Christelle de la Fouchardière, Simon Thézenas, et al.
BMC Cancer
|
April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Stefano Kim, Bruno Buecher, Thierry André, et al.
Cancers
|
October 13, 2021
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM
Guillaume Belthier, Zeinab Homayed, Fanny Grillet, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Cancers
|
April 12, 2022
Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma
Marc Hilmi, Cindy Neuzillet, Jérémie H Lefèvre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
Alice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Experimental Hematology & Oncology
|
July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Stefano Kim, Véronique Vendrely, Angélique Saint, et al.
Cancer Treatment Reviews
|
July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective
Judith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
Lancet (London, England)
|
June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial
Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
The Lancet. Oncology
|
April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study
Mélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Clinical Colorectal Cancer
|
August 2, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
Emmanuelle Samalin, Christelle de la Fouchardière, Simon Thézenas, et al.
BMC Cancer
|
April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Stefano Kim, Bruno Buecher, Thierry André, et al.
Cancers
|
October 13, 2021
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM
Guillaume Belthier, Zeinab Homayed, Fanny Grillet, et al.
Page
of 7